导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.24% | 2664/4407 |
| 近一周 | -1.88% | 3351/5016 |
| 近一月 | -2.76% | 960/4972 |
| 近一季 | -1.15% | 1027/4811 |
| 近半年 | -0.57% | 1589/4547 |
| 近一年 | 1.38% | 2086/4077 |
| 近两年 | 40.03% | 1744/2754 |
| 近三年 | 26.81% | 1102/2082 |
| 成立以来 | 31.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.06% 4019/4961 |
7.80% 2665/5312 |
- - |
- - |
| 2025 | 17.28% 2391/4813 |
-0.46% 2259/3635 |
3.10% 1169/4076 |
11.54% 3150/4524 |
2.45% 947/4813 |
| 2024 | 19.05% 560/3463 |
3.70% 523/2808 |
0.03% 652/3014 |
17.31% 1213/3129 |
-2.17% 1985/3463 |
| 2023 | -8.34% 1001/2656 |
1.01% 1659/2280 |
-4.37% 1153/2385 |
1.84% 271/2515 |
-6.83% 1938/2655 |
| 2022 | -16.81% 516/2207 |
-11.39% 506/1919 |
6.65% 644/2016 |
-13.35% 889/2113 |
1.59% 1210/2208 |
| 2021 | -6.67% 1017/1822 |
-2.74% 697/1255 |
0.61% 1091/1330 |
-6.94% 1009/1466 |
2.49% 578/1822 |
| 2020 | 26.57% 603/1250 |
-11.15% 820/1028 |
11.55% 725/1067 |
12.75% 366/1164 |
13.26% 376/1184 |
| 2019 | 38.07% 320/1092 |
23.60% 545/754 |
4.42% 29/804 |
0.78% 469/850 |
6.15% 650/918 |
| 2018 | -17.38% 130/834 |
- - |
- - |
- - |
-12.12% 404/691 |
| 2017 | 30.41% 58/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.33% 140/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 博时上证50ETF VS. 长安沪深300非周期A(740101) |